Citigroup has given a ‘buy’ rating on Divis Laboratories with the target price at Rs 7,050. Analysts feel the company has high potential to become the primary supplier given capacity addition. Orforglipron, Eli Lilly’s potential best-in-class oral GLP-1, is the next addition in Divi’s pipeline. They expect more rounds of capex with scale up in products. The stock is the top pharma pick.
CLSA has a ‘hold’ call on Tata Consumer with a target price of Rs 1,044. Analysts said Jan-March net sales was up 17% on the year which was broadly in-line, along with the company’s gross profit. However, gross margin missed guidance due to high input costs while EBITDA was below estimates due to higher other expenses.
ICICI Securities has retained its ‘hold’ rating on LTIMindtree with a revised target price of Rs 4,410. Analysts said LTIM reported muted performance for Jan-March with lower revenue growth. Slower growth came on the back of delayed ramp-up and deferral of deals, ramp-down in healthcare vertical, top-5 clients’ revenue declining from AI-led gain sharing. LTIM expects the deferred deals to come through in the current quarter. CEO designate’s three-pronged strategic emphasis on efficiency is expected to improve margin.
HSBC has a ‘reduce’ call on Bajaj Housing Finance with the target price at Rs 100. Analysts said the housing finance company’s quarterly AUM growth was healthy but high cost ratio and yield compression due to competition were drags on its results. They expect EPS growth to slow due to pressure on AUM growth, NIM compression, and normalisation of credit costs.
Nomura has given a ‘buy’ rating on Anant Raj Industries but with a lowered target price at Rs 700 due to reduced fund-raising visibility. Analysts feel the stock is still an attractive bet despite a more conservative stance on the data center segment. They said internal accruals would fund 50% of the company’s capex requirement. It has got a robust residential launch pipeline for FY26.
Disclaimer: The opinions, analyses and recommendations expressed herein are those of brokerage and do not reflect the views of The Times of India. Always consult with a qualified investment advisor or financial planner before making any investment decisions.
CLSA has a ‘hold’ call on Tata Consumer with a target price of Rs 1,044. Analysts said Jan-March net sales was up 17% on the year which was broadly in-line, along with the company’s gross profit. However, gross margin missed guidance due to high input costs while EBITDA was below estimates due to higher other expenses.
ICICI Securities has retained its ‘hold’ rating on LTIMindtree with a revised target price of Rs 4,410. Analysts said LTIM reported muted performance for Jan-March with lower revenue growth. Slower growth came on the back of delayed ramp-up and deferral of deals, ramp-down in healthcare vertical, top-5 clients’ revenue declining from AI-led gain sharing. LTIM expects the deferred deals to come through in the current quarter. CEO designate’s three-pronged strategic emphasis on efficiency is expected to improve margin.
HSBC has a ‘reduce’ call on Bajaj Housing Finance with the target price at Rs 100. Analysts said the housing finance company’s quarterly AUM growth was healthy but high cost ratio and yield compression due to competition were drags on its results. They expect EPS growth to slow due to pressure on AUM growth, NIM compression, and normalisation of credit costs.
Nomura has given a ‘buy’ rating on Anant Raj Industries but with a lowered target price at Rs 700 due to reduced fund-raising visibility. Analysts feel the stock is still an attractive bet despite a more conservative stance on the data center segment. They said internal accruals would fund 50% of the company’s capex requirement. It has got a robust residential launch pipeline for FY26.
Disclaimer: The opinions, analyses and recommendations expressed herein are those of brokerage and do not reflect the views of The Times of India. Always consult with a qualified investment advisor or financial planner before making any investment decisions.
You may also like
'Terrorism a global menace, needs to be addressed in unison', says VP Dhankhar
Capital DJ gets life-changing diagnosis after skipping doctors for lash appointment
Debenhams reduce £720 watch to £86 so 'beautiful' it gets shoppers 'several compliments'
Breakthrough in lab-grown blood could mean UK no longer needs to rely on human donations
Nepal Medical Association announces boycott of non-emergency medical services
